You will be seen by your surgeon and/or medical oncologist at the outpatient unit in the National Cancer Centre Singapore at approximately 1-2 weeks after the surgery, and at least every 3 months thereafter for 1 year. Subsequently the frequency of your visits will decrease if you are well. Systemic chemotherapy will be offered by your medical oncologist if you are suitable. CT scans of your body, along with blood tests may be done at each follow-up visit. Appointments with other medical practitioners may also be arranged for you.
The major centers who perform CRS and HIPEC are mainly in the USA and Europe. To our knowledge, we have one of the largest experience in Asia. The risk of a major complication in these centers ranges from 10 to 45%, while the mortality rate ranges from 0 to 3.5%.
According to data from various centers around the world, the median 5 year survival for patients undergoing CRS and HIPEC for colorectal cancers, ovarian cancers and pseudomyxoma peritonei is 42% (20-51%), 25.4% and 87% respectively.
Since 2001, the Department of Surgical Oncology at the National Cancer Centre Singapore, has performed more than 100 CRS and HIPEC procedures for peritoneal disease from colorectal, ovarian, appendiceal, pseudomyxoma peritonei, primary peritoneal and mesothelioma patients. Our post-operative mortality rate is 2%. Our overall survival rate for 1, 3 and 5 years after CRS and HIPEC is 91.7%, 59.1% and 50.9% respectively.
For more information on Peritoneal based Malignancies, watch our video.
The information provided on this page does not replace information from your healthcare professional. Please consult your healthcare professional for more information.
Information provided by
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000